Close menu




October 26th, 2020 | 11:28 CET

Adva Optical Networking, Desert Gold, Va-Q-tec: Does it start now?

  • Investments
Photo credits: pixabay.com

"Good numbers, bad numbers." What does that even mean? Often it is the figures or news the Companies publish, only the deviation from expected values or developments. Ultimately, the decisive factor is whether or not a company passes the bar. But the devil is in the details. Here are three companies that have benefited from positive figures or news or where a good news flow is only a matter of time. Who offers the best opportunities?

time to read: 2 minutes | Author: Carsten Mainitz
ISIN: CA25039N4084 , DE0005103006 , DE0006636681

Table of contents:


    ADVA OPTICAL NETWORKING SE - are there any more positive surprises in store?

    Adva Optical Networking is a leading provider of open network solutions for the delivery of cloud and mobile services. Last Wednesday the Company published its figures for the third quarter. With a minimal increase in sales to EUR 146.7 million, pro forma operating earnings rose by 49.5% year-on-year to EUR 7.4 million. Adva thus continued the strong profitability achieved in the second quarter. According to the Company's statement, both substantial cost reductions and new customer business led to the progress made.

    Adva also updated its outlook for the year as a whole. The group now expects to post sales of between EUR 565 and 580 million in 2020. The margin based on pro forma operating profit is expected to be 5% to 6%. In Q3, an increase from 5.1% to 7.4%, was achieved. The old forecast for the full year, which was for sales of more than EUR 580 million and a margin target of more than 5%, was capped in April.

    All in all, Adva delivered excellent figures. The increase in margins is impressive. Looking at the margin of 7.4% in Q3, the target of 5% to 6% for the year as a whole already seems modest. Adva should be able to leap over this benchmark and once again surprise investors positively.

    DESERT GOLD VENTURES INC - good entry point after price correction

    The gold explorer Desert Gold Ventures focuses entirely on the West African country of Mali. The Company is exploring two promising projects SMSZ and Djimbala in the south. Several big names such as Barrick, B2Gold, Endeavour, and Resolute have also committed themselves to the activity in Mali. Already in August, Desert Gold was able to carry out a capital increase of CAD 6.8 million. In late September, the TSX-V-listed Company released positive drill results.

    After a brilliant performance this year, which peaked in the summer at CAD 0.32, the share price dropped significantly to CAD 0.16. The market capitalization is currently CAD 21 million.

    Given the intact fundamental environment for gold and the excellent project quality, there is a perfect opportunity for investors to become involved after the significant price setback. Good news is only a matter of time.

    VA-Q-TEC AG - Profiteer of temperature-sensitive corona vaccines

    Va-Q-tec AG is a supplier of vacuum insulation panels and thermal energy storage components, as well as thermo boxes and containers for the transport of temperature-sensitive goods. The Würzburg-based Company's applications are essential for customers in the pharmaceutical sector, among others, because medicines should not be exposed to high-temperature fluctuations during transport to ensure the effectiveness of the ingredients.

    The Systems division (sale of thermoboxes) grew dynamically by 77% year-on-year in the first half of the current fiscal year. It contributed 10.5 million to total sales of EUR 35.7 million Euro (previous year: EUR 31.3 million). The Company will publish the reporting data for the third quarter on November 12.

    The following is the basis of the Goldylocks scenario for the share: If temperature-sensitive Corona vaccines were to become available soon, the Würzburg-based Company would undoubtedly benefit from this through its services. Currently, a good 2/3 of the customers are already from the pharmaceutical industry. This share would then increase significantly. With prices of around EUR 24.00, the share has already priced in quite a bit, but not everything.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read